Pilot study seeks to validate new and more granular outsourcing model classifications in differentiating performance across custom contract-service approaches.
The era of big pharma as product-first companies must end, as services become the larger priority.
Findings from an OCT Clinical survey of researchers from 61 sites in Russia to gain the perspective of an investigator regarding clinical trials during the COVID-19 pandemic.
Successful collaborations between Pharma/Biotech/Device industries and CROs will play a key role in an effective fight against the global COVID-19 pandemic.
The cost and benefits for patients and sponsors in using ePRO versus paper
What is next for DCTs after acceleration from COVID-19?
A discussion of the regulatory history behind audit trails and its interpretation as it relates to clinical research data originating or residing in EDC or eCOA systems.
Expanding clinical trial access to include historically underrepresented ethnic and racial minorities means addressing root-cause barriers, including taxation.
Decentralized clinical trials have the potential to expand the number of people who can benefit from clinical trials while accelerating therapies to more patients in need.
Tufts CSDD study finds that acts of microaggression negatively impact psychological safety and performance.
Survey study of eight biopharma companies aimed to identify how often technology is being used in cancer trials.
Tony Clapsis, SVP and General Manager, CVS Clinical Trial Services, reflects on industry’s progress.
2020 Tufts CSDD – IBM Watson Health benchmarking study highlights need for new functionality from EDC solutions and providers.
In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Approaches sponsors, CROs, and investigators can take from the DMD experience.
COVID-19 forces life sciences industry to make long overdue changes.
Tufts Center for the Study of Drug Development and Biogen recently conducted a study to inform growing interest in improving diversity of clinical trial participation. The results of this research provide insights into increasing the community of minority investigators and study staff and presenting greater access to clinical trials among minority study volunteers.
Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.
Following a discussion around summarization in Part 1, Part 2 discusses the method of pure abstraction in light of recent advances in deep learning and AI.
Three case studies showcase ability of AI and ML in overcoming challenges with data, resourcing, and more.
Ensuring equitable access to new technologies and integrating AI to benefit all communities remain critical challenges to overcome.
If a future Supreme Court ruling on diversity were to be applicable to clinical research, the FDA’s positions on diversity will take on even more importance.
Site and project management teams play major roles in risk-management and monitoring performance.
In new age of digital, investigators must carefully create strategies to keep engagement high.
A look at the issues in Europe affecting ongoing trials including data management, measures being taken by sponsors, and more.
Sponsors need to develop a strategy on how to evaluate the impact of the pandemic on the re-start of halted trials.
Navigating FDA’s draft guidance and heightened diversity recommendations.
What are the necessary next steps—for all parties involved—in improving diversity in clinical trials?
A 1-year observational follow-up of a 3-month RCT provides insight into he benefits of advanced hybrid closed-loop system use in people with type 1 diabetes using multiple daily injections and self-monitoring of blood glucose.
While televisits can address many medical concerns, one frequent reservation expressed by healthcare professionals is that patients during these televisits tend to present too narrow a picture of their clinical condition-resulting in non-comprehensive medical assessments.